Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Graves’ Disease Pharmacotherapy in Women of Reproductive Age
authors: Prunty JJ, Heise CD, Chaffin DGsummary/abstract:
Graves’ disease is an autoimmune disorder in which inappropriate stimulation of the thyroid gland results in unregulated secretion of thyroid hormones resulting in hyperthyroidism. Graves’ disease is the most common cause of autoimmune hyperthyroidism during pregnancy. Treatment options for Graves’ disease include thioamide therapy, partial or total thyroidectomy, and radioactive iodine. In this article, we review guideline recommendations for Graves’ disease treatment in women of reproductive age including the recent guideline from the American College of Obstetricians and Gynecologists.
Controversy regarding appropriate thioamide therapy before, during, and after pregnancy is reviewed. Surgical and radioactive iodine therapy considerations in this patient population are also reviewed. In patients who may find themselves pregnant during therapy or develop Graves’ disease during their pregnancy, consideration should be given to the most appropriate treatment course for the mother and fetus. Thioamide therapy should be used with either propylthiouracil or methimazole at appropriate doses that target the upper range of normal to slightly hyperthyroid to avoid creating hypothyroidism in the fetus.
Consideration should also be given to the adverse effects of thioamide, such as agranulocytosis and hepatotoxicity, with appropriate patient consultation regarding signs and symptoms. Individuals who wish to breastfeed their infants while taking thioamide should receive the lowest effective dose. Surgery should be reserved for extreme cases and limited to the second trimester, if possible. Radioactive iodine therapy may be used in nonpregnant individuals, with limited harm to future fertility. Radioactive iodine therapy should be withheld in pregnant women and those who are actively breastfeeding. Clinicians should keep abreast of developments in clinical trials and evidence-based recommendations regarding Graves’ disease in reproductive-age women for any changes in evidence-based practice.organization: West Virginia University School of Pharmacy, USA; Cabell Huntington Hospital, USA; Marshall University School of Pharmacy, USA; Joan C. Edwards School of Medicine at Marshall University, USA
Treatment of Hyperthyroidism With Antithyroid Drugs Corrects Mild Neutropenia in Graves’ DiseaseContext: Neutropenia secondary to antit...
Relation Between Therapy for Hyperthyroidism and the Course of Graves’ OphthalmopathyBackground: The chief clinical characte...
David Schneider, MD, MS, FACSDr. Schneider is certified by the Americ...
A Walk Through Autoimmunityhttps://www.youtube.com/watch?v=yZ6wWuAQ...
Anthony Maloof, MBBS hons, MBiomedE, FRANZCODr. Maloof is an internationally recogni...
Surgical Treatment of Diplopia in Graves’ Orbitopathy PatientsPurpose: To review the authors' current...
The Second Antithyroid Drug Treatment is Effective in Relapsed Graves’ Disease Patients: A Median 11-Year Foll...Background: Antithyroid drug (ATD) is a...
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.